What The AI-Mind project does

The AI-Mind project (legal name: AI-Mind – Artificial Intelligence for Dementia Prevention) is a European research consortium that developed and clinically validated two AI-based digital tools for early dementia risk assessment in people with Mild Cognitive Impairment (MCI). Coordinated by Dr. Ira Haraldsen at Oslo University Hospital, the project ran from March 2021 to February 2026 under Horizon 2020 Grant Agreement No 964220 with an allocated budget of approximately €14 million. It assembled 17 partners across 8 European countries, including leading hospitals (Oslo University Hospital, Helsinki University Hospital, IRCCS San Raffaele Roma), research universities (Complutense University of Madrid, Università Cattolica del Sacro Cuore, Aalto University, University of Oslo), SMEs (BrainSymph AS, Neuroconnect Srl, Lurtis Rules, Pre Diagnostics, accelopment Schweiz AG), patient advocacy (Alzheimer Europe), and industry (Roche for blood biomarker cross-validation).

The technical core of the project is two complementary AI tools. The AI-Mind Connector processes EEG (and related MEG) brain imaging data to evaluate and visualise interactions between brain areas, identifying early disturbances in functional brain networks. The AI-Mind Predictor combines Connector outputs with cognitive test results and blood biomarker analysis to produce individual dementia risk predictions with reported accuracy above 95%, using probabilistic machine learning and deep learning approaches. Both tools are integrated into a cloud-based diagnostic support platform administered via the University of Oslo's Services for Sensitive Data (TSD) infrastructure, designed for intuitive use by healthcare professionals, and are positioned for integration into the EBRAINS research infrastructure. The AI models were trained and validated on a multinational clinical dataset of more than 1,000 MCI participants recruited across Norway, Finland, Italy, and Spain.

AI-Mind is not a commercial company and operates no pricing or revenue model. Its sole funding source was the EU Horizon 2020 grant, and it has no paying customers; clinical study participation was free to enrolled patients. Go-to-market is event- and dissemination-driven rather than commercial: the consortium engaged healthcare professionals, policymakers, and patient organisations through conferences (Alzheimer Europe, CTAD, NeurIPS), webinars, multilingual newsletters, policy briefs (including a launch at the European Parliament), and the AI-Mind Share knowledge hub. The project received the first-ever Award for Excellence in Clinical Trials ('Innovative Environment of the Year') from the Norwegian Pharmaceutical Industry Association in early 2026. Operating status is reported as closed following the formal project end in February 2026, with tools transitioning to EBRAINS for downstream research and potential clinical adoption.

Name

The AI-Mind project

Legal name

AI-Mind (Artificial Intelligence for Dementia Prevention)

Website

https://ai-mind.eu

Company type

Private

Founded year

2021

Operating status

Closed

Headcount range

11–50 employees

Short description

The AI-Mind project is a European Horizon 2020 research consortium that developed and clinically validated two AI-based digital tools—the Connector and the Predictor—for early dementia risk assessment in patients with Mild Cognitive Impairment, serving healthcare professionals across Norway, Finland, Italy, and Spain.

Ownership category

akta.pro rank

Product category

AI-based Clinical Decision Support for Neurology

NAICS

Computing Infrastructure Providers, Data Processing, Web Hosting, and Related Services (5182)

SIC

Services-Computer Integrated Systems Design (7373)

akta.pro primary industry

Medical Imaging AI (HDAAAEAH)

akta.pro secondary industry

End-to-End Enterprise AI Platforms (MLOps & Model Lifecycle Management) (HDAEANAA)

Keywords

• AI dementia diagnostics
• Cognitive risk assessment
• Brain connectivity analysis
• Clinical decision support
• Neurodegenerative disease screening

Headquarters

HQ city

Oslo

HQ country

Norway

HQ region

Europe

Offices5 records

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Horizon 2020 Research Funding: The AI-Mind project is a Research and Innovation Action (RIA) funded by the European Union's Horizon 2020 research and innovation programme under grant agreement No 964220, with a budget of approximately 14 million euros over five years (2021-2026). The project concluded at the end of February 2026.
2. Non-commercial Research Output: The project developed AI tools for clinical use without commercial revenue generation. The tools aim to enable early dementia risk assessment in healthcare systems, with potential for future integration into clinical practice.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels8 records

Core offering

The AI-Mind project developed two AI-based digital tools — the AI-Mind Connector (analyses EEG data to evaluate functional brain connectivity) and the AI-Mind Predictor (combines brain connectivity, cognitive tests, and blood biomarker data to provide dementia risk prediction with greater than 95% accuracy) — integrated into a cloud-based diagnostic platform intended for use by healthcare professionals to identify people with Mild Cognitive Impairment at elevated risk of developing dementia.

Product overview

AI-Mind is a European research project developing two complementary AI-based digital tools integrated into a cloud-based diagnostic support platform. The AI-Mind Connector processes electroencephalography (EEG) brain imaging data to evaluate and visualise interactions between different brain areas, identifying early disturbances in functional brain networks. The AI-Mind Predictor combines data from the Connector with cognitive tests and blood biomarkers to provide dementia risk predictions with >95% accuracy for clinical decision-making. Both tools are integrated into a user-friendly cloud platform designed for health professionals to enable earlier and more precise dementia risk assessment for patients with Mild Cognitive Impairment (MCI).

Differentiator

Problem solved

Functional benefit

Brands

• AI-Mind Connector: An AI-based digital tool that evaluates and visualises interactions between different brain areas using EEG data, identifying early disturbances in the functional brain network as signs of cognitive changes that may develop into dementia.
• AI-Mind Predictor
• AI-Mind Share

Products and services

• AI-Mind Connector An AI-based digital tool fed with brain images from electroencephalography (EEG) data that evaluates and visualises interactions between different brain areas, identifying early disturbances in the functional brain network as the first signs of cognitive changes that may develop into dementia. Targeted at healthcare professionals for clinical decision support.
• AI-Mind Predictor An AI-powered tool that combines data from the AI-Mind Connector, cognitive tests, and blood analysis to provide accurate (>95%) prediction of dementia risk for clinical decision-making for people with Mild Cognitive Impairment. Targeted at healthcare professionals (neurologists, geriatricians, clinical researchers).
• AI-Mind Cloud-Based Diagnostic Platform A cloud-based diagnostic support platform that integrates the AI-Mind Connector and AI-Mind Predictor tools into an easy-to-implement service for health professionals, featuring a user-friendly design and intuitive software. Validated in clinical settings and administered by the University of Oslo Services for Sensitive Data (TSD) for secure data handling.

Quantifiable outcome

• Dementia risk prediction accuracy >95%
• +2 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature5 records

Partnerships

20 partnerships are on record, tiered core and supporting.

• Oslo University Hospital (OUS)coreStrategic or Co-development Partner · 1 March 2021Lead coordinator of AI-Mind, responsible for overall coordination, communication and management of the project. The Cognitive Health Research group leads clinical trials and the Legal Department leads WP1 on legal and clinical guidelines.
• Helsinki University Hospital (HUS)coreStrategic or Co-development Partner · 1 March 2021The largest hospital in the Nordic countries with 27,000 employees. Contributes to medical research and innovation strategies strengthening AI and digitalization in patient care and preventive medicine.
• IRCCS San Raffaele PisanacoreStrategic or Co-development Partner · 1 March 2021Devoted to guarantee excellent care in neurorehabilitation with a cutting-edge facility for translational research. Specializes in brain connectivity and cognitive decline assessment.
• Complutense University of Madrid (UCM)coreStrategic or Co-development Partner · 1 March 2021One of the largest universities in Europe with research resources in neuroscience including the Laboratory of Cognitive and Computational Neuroscience (LNCyC) specializing in MEG, EEG, and DTI-MRI imaging.
• Università Cattolica del Sacro Cuore (UCSC)coreStrategic or Co-development Partner · 1 March 2021Participates with Graduate School of Health Economics and Management (ALTEMS) and Memory Clinic handling over 4,000 outpatients yearly with cognitive disorders. Provides health technology assessment expertise.
• Tallinn University (TLU)supportingTechnology or Integration · 1 March 2021Third-largest university in Estonia with School of Digital Technologies conducting research in Digital Learning Ecosystems and Human-Computer Interaction.
• Aalto UniversitysupportingTechnology or Integration · 1 March 2021Finnish university committed to identifying grand societal challenges with strong technology and AI research capabilities.
• NordSTAR (Nordic Centre for Sustainable and Trustworthy AI Research)supportingTechnology or Integration · 1 March 2021Centre of research excellence at Oslo Metropolitan University focused on Sustainable and Trustworthy AI with five research groups including Explainable AI and Human factors in AI.
• Lurtis Rules S.L.supportingTechnology or Integration · 1 March 2021R&D-driven company based in Spain and UK committed to creating AI-driven solutions for engineering and science sectors, including early dementia prediction.
• BrainSymph ASsupportingTechnology or Integration · 1 March 2021Medical technology commercialization enterprise founded by neuroscience researchers from Oslo University Hospital, specializing in state-of-the-art EEG with focus on functional brain connectivity.
• Neuroconnect SrlsupportingTechnology or Integration · 1 March 2021Spin-off of Catholic University of the Sacred Heart of Rome, founded in 2018, focusing on brain connectivity and assessment of cognitive decline in MCI, Alzheimer and Stroke patients.
• Alzheimer Europe (AE)coreStrategic or Co-development Partner · 1 March 2021Non-governmental organisation with 39 member national Alzheimer associations in 35 countries. Provides ethical discussions, represents views of people with dementia, and supports communication to public and policymakers.
• accelopment Schweiz AGcoreImplementation/ SI/ Consulting Partner · 1 March 2021Swiss SME assisting in EU project management and dissemination/exploitation of project results. ISO 9001 certified with over 25 years experience in Horizon 2020 projects.
• Radboud University Medical Center (RUMC)supportingStrategic or Co-development Partner · 1 March 2021Academic hospital in Nijmegen, Netherlands, part of Dutch Federation for university medical centres, focused on innovative and sustainable healthcare development.
• Pre Diagnostics (PREDX)supportingTechnology or Integration · 1 March 2021Norwegian-based SME specializing in fluid dementia biomarkers, contributing blood analyses on samples from 1,000 study participants for AI model development.
• University of Oslo (UiO)coreTechnology or Integration · 1 March 2021Norway's highest-ranked university providing Services for Sensitive Data (TSD) for secure data handling. Administering the AI-Mind platform once deployed.
• RochecoreStrategic or Co-development Partner · 1 March 2021Global pioneer in pharmaceuticals and diagnostics providing blood biomarker analysis (NeuroToolKit assays including P-tau 181) supporting cross-validation of study samples.
• Human Brain ProjectsupportingStrategic or Co-development Partner · 1 March 2021EU flagship initiative aiming to understand the human brain and its diseases. Partnership supports AI tools development aligned with European Digital Health strategy.
• EBRAINSsupportingTechnology or Integration · 1 March 2021Open research infrastructure gathering data, tools and computing facilities for brain-related research, built with interoperability at the core. AI-Mind tools being integrated into EBRAINS.
• HEALTH DATA CLOUDsupportingTechnology or Integration · 1 March 2021Horizon Europe project focusing on creating a decentralized, data protection-compliant research platform for brain health.

Scale indicators8 records

Recent moves5 records

Expansion highlights4 records

Emerging players

• Quanterix: Ultra-sensitive immunoassay platform for blood-based biomarkers of neurological disease including Alzheimer's. Comparable as an emerging diagnostic modality for early dementia detection, with a different technology (blood biomarkers vs EEG).

Broad incumbents

• Roche: Global pharmaceutical and diagnostics leader with established Elecsys blood-based Alzheimer's biomarker assays (pTau181) and a major AI-Mind consortium partner. Comparable as both a blood-biomarker competitor and a potential commercialization partner for AI-Mind.
• Biogen: Global biotechnology company with leading Alzheimer's therapies (Leqembi) and major interest in companion diagnostics. Comparable as a major incumbent in the Alzheimer's treatment paradigm that AI-Mind's diagnostic could feed into.

Direct peers

• C2N Diagnostics: US-based diagnostics company offering PrecivityAD, a blood-based test for Alzheimer's disease detection. Directly comparable as an early-detection dementia diagnostic and was named as a joint webinar partner with AI-Mind, indicating overlap in target clinical users.
• Altoida: Digital cognitive assessment platform using AI/ML on smartphone-based tasks to predict MCI-to-dementia conversion. Comparable in targeting the MCI-to-dementia prediction pathway with an AI/ML diagnostic, but uses digital cognitive markers rather than EEG/MEG.
• BrainCheck: Digital cognitive assessment platform for concussion and dementia screening, with FDA-cleared products. Comparable in providing clinician-facing cognitive assessment tools targeting early dementia detection.
• Icometrix: Belgian AI medical imaging company focused on brain MRI/CT analysis for neurological disorders including multiple sclerosis and dementia. Most directly comparable to AI-Mind in terms of applying AI to brain imaging for neurodegenerative disease diagnostics.
• Cambridge Cognition: UK neuroscience company providing digital cognitive assessment tools for clinical trials and healthcare. Comparable in providing cognitive testing infrastructure integrated into clinical workflows for early dementia detection.
• Ixico: AI-driven imaging analytics for neurological disorders including Alzheimer's disease, with established clinical trial and pharmaceutical partnerships. Comparable in applying AI to brain imaging for dementia clinical research and diagnostics.
• Linus Health: Boston-based digital health company applying AI to cognitive assessment for early detection of dementia and Alzheimer's. Directly comparable in serving the MCI screening use case with a clinician-facing diagnostic platform.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/AIMind_eu
• YouTubeyoutube.com/channel/UCmBRPkVE8TMqYYE5bckOHlg
• Facebookfacebook.com/AIMindEU
• LinkedInlinkedin.com/company/ai-mind-project
• Instagraminstagram.com/ai_mind_eu

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about The AI-Mind project